Unicycive Therapeutics, Inc. UNCY

Management knew they couldn't pass and would get a CRL. That’s why they kept using ATM while the price was high. Gupta has to go and needs to be put in jail.

Looks like smart people don’t want their money stuck in a company where the management team is so incompetent. Gupta has to go.

If i had spare money i wd have piled up more shares. Not selling mine

Actually, it’s quite clear. Gupta has to go. He lacks the competence to run this company. Don’t forget they know that the FDA has not yet inspected the manufacturing factory, and that’s why they keep using an ATM offering to cash out money from the market. This is fraud, and we should stand up to sue him and the company.

So could UNCY management be responsible?

Yes — in at least three ways:

1. Vendor selection and qualification

If the vendor had a weak compliance history, UNCY chose them. Sponsors must evaluate:

• past FDA inspection outcomes
• data integrity history
• cGMP culture
• readiness for pre‑approval inspection

If any of these were suboptimal, that is a management decision.

1. Vendor oversight and auditing

Sponsors must perform:

• routine audits
• remediation verification
• mock inspections
• documentation reviews
• readiness assessments

If FDA arrived and found the vendor not ready — or didn’t arrive because readiness was unclear — that is a sponsor oversight failure.

1. Regulatory strategy and timing

UNCY resubmitted the NDA before FDA had inspected the vendor.
This is a strategic choice.

If the vendor was not realistically going to be inspected within the review window, the resubmission was premature. The subtle but important nuance

This does not mean UNCY management acted negligently.
It means:

• FDA assigns responsibility to the sponsor
• industry norms expect the sponsor to manage vendor risk
• failure to secure an inspection within the review cycle is ultimately a sponsor‑level failure, even if the vendor did everything right

In other words:UNCY may not be “at fault”, but they are absolutely “responsible”.

CoPilot assessment of press release

The FDA never went back and re‑inspected the problematic manufacturing site during the review of the resubmitted NDA — so the agency could not clear the CMC deficiency, and therefore had no choice but to issue another CRL repeating the same problem. The key line:

“the FDA has not yet conducted its inspection of that third‑party manufacturing vendor as part of the review process of the resubmitted NDA”

This is regulatory code for a very specific situation:

1. The resubmission depended on the vendor being inspection‑ready

Unicycive resubmitted the NDA on the assumption that the original vendor had fixed its cGMP deficiencies and was ready for FDA inspection.
But inspection readiness is not the same as inspection completed.

1. FDA must inspect the facility before approving the NDA

For any drug product, FDA must confirm that the manufacturing site complies with cGMP.

If the site previously failed, FDA must perform a re‑inspection (or rely on recent inspection history) before clearing the CMC deficiency. If the inspection doesn’t happen, the deficiency cannot be resolved.

1. FDA did not inspect the vendor during the review clock

This is the critical point.
If FDA hasn’t inspected the facility, then:

• FDA cannot verify remediation
• FDA cannot sign off on the CMC section
• FDA cannot approve the NDA
• FDA must issue a CRL, even if the drug’s clinical data is perfect

This is why the CRL repeats the same deficiency as 2025 — not because the vendor failed again, but because FDA never performed the inspection required to confirm the fix.

1. Why would FDA not inspect?

Several common reasons:

• Scheduling constraints — FDA inspection resources are limited, and small‑company CDMOs often get lower priority.
• Inspection backlog — post‑COVID, FDA still has uneven inspection cadence for foreign and small‑scale facilities.
• Vendor readiness uncertainty — FDA may have wanted more documentation before committing to an inspection.
• Risk‑based prioritisation — phosphate binders are not high‑risk products; FDA may have prioritised other inspections.
• Geographic or logistical issues — if the vendor is overseas, inspection scheduling can be slow.

None of these imply the vendor failed — only that FDA didn’t get to them.

1. Regulatory translation. The sentence is essentially saying:

“We didn’t get inspected, so FDA couldn’t approve us.”

It is not saying:

• the vendor failed the inspection
• the vendor wasn’t ready
• FDA found new problems
• FDA questioned the drug itself

It is purely a procedural failure: no inspection = no approval.

Why Unicycive emphasised this in the press release. Because it reframes the CRL as:

• not a scientific failure
• not a safety failure
• not a clinical failure
• not a new CMC failure

but simply:

• an administrative timing failure

This is the most “forgiving” type of CRL from a market‑perception standpoint.

---

The deeper regulatory nuance

FDA’s acceptance of the resubmission (Class II, 6‑month review) usually signals that the agency believes the remediation package is complete enough to review.
But acceptance does not guarantee an inspection will occur within the review window.

If the inspection doesn’t happen, the NDA cannot be approved — even if everything else is perfect.

This is why the CRL wording mirrors the 2025 CRL: the deficiency was never re‑evaluated.

This is quite clear. CEO has to step down to take responsibility. Gupta has to go!

Speechless...

Gupta should be in JAIL for his incompetence and dishonesty.

Are there any law firms that can represent us to sue this company and Gupta into the ground? Please contact us.